Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT07244926
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Sacituzumab tirumotecan plus bevacizumab
Sponsor
Tianjin Medical University Cancer Institute and Hospital